The US Food and Drug Administration (FDA) has approved the novel calcimimetic etelcalcetide (Parsabiv, Amgen) for the treatment of secondary hyperparathyroidism in adults on hemodialysis.

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo (Reuters) - The U.S. Food and Drug Administration has ...

Please provide your email address to receive an email when new articles are posted on . A lower parathyroid hormone target treatment method was linked with reduced adjusted hazard of death. The ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent Roux-en-Y gastric bypass who were also vitamin D deficient had an increased risk for ...

In a retrospective study, investigators found that radiofrequency ablation and parathyroidectomy for secondary hyperparathyroidism in patients on dialysis achieved intact parathyroid hormone levels in ...

This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar ®), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Secondary Hyperparathyroidism - Pipeline ...

dialysis hemodialysis machine The hospitalization rate and number of hospital days increased significantly in the year after parathyroidectomy vs the year before, whereas dialysis visits and office ...

SECONDARY hyperparathyroidism associated with chronic renal disease may simulate primary hyper-parathyroidism with secondary renal impairment in virtually every particular. An exception is the brown ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The latest Pharmaceutical and Healthcare ...